Choosing to participate in a clinical trial is one of the most significant decisions a patient can make — it offers access to treatments years before they reach the market, but only when you understand the process, know what questions to ask, and can distinguish registered research from marketing dressed up as science.

What Is a Stem Cell Clinical Trial, Exactly?

A clinical trial is a regulated research study designed to answer a specific question about a medical intervention — in this case, mesenchymal stem cell therapy. Unlike treatment at a commercial clinic, a trial follows a formal protocol approved by ethics committees and regulatory agencies. Every dose, every assessment time point, and every safety reporting procedure is pre-specified and monitored. [1]

Trials exist on a spectrum of evidence generation. Phase I studies focus on safety and dosing — "what is the maximum safe dose?" Phase II explores efficacy signals — "does it work for this condition?" Phase III compares the treatment against a placebo or standard of care in a large population. Phase IV studies, sometimes called post-marketing surveillance, continue monitoring after regulatory approval. Each phase answers a different question, and patients should know which phase they are considering. [2]

The critical difference between a trial and commercial treatment is oversight. A legitimate trial has an independent Data Safety Monitoring Board, a published protocol on a public registry, and an ethics committee that can halt the study if safety signals emerge. A commercial clinic offering "clinical experience" may use scientific language but lacks these protections. Knowing the difference is the foundation of informed participation. [3]

Key principle: If a program calls itself a "clinical trial" but is not listed on a public registry like ClinicalTrials.gov, it is not a trial — it is a commercial treatment using the language of research to market itself.

How to Find Legitimate MSC Clinical Trials

The primary global registry for clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. As of 2026, it lists over 1,200 MSC-related studies across 60 countries. Every legitimate trial — whether Phase I, II, III, or IV — must register before enrolling its first patient. A search for "mesenchymal stem cells" plus your condition yields the most relevant results. [4]

The WHO International Clinical Trials Registry Platform aggregates registries from 17 countries. For trials outside the United States, the WHO ICTRP is the most comprehensive search tool. Many European trials appear on the EU Clinical Trials Register; trials in China, Japan, and Korea use their national registries. If a trial appears on none of these platforms, it has not met the basic transparency standard expected of legitimate research. [5]

Reading a trial listing requires a few key pieces of information. The "Recruitment Status" tells you whether the trial is actively enrolling, completed, or terminated. "Phase" tells you where it sits in the evidence pipeline — early-phase studies carry more uncertainty. "Sponsor" identifies who is funding and running the study — an academic medical center carries different implications than a commercial entity. "Locations" tells you where you would need to travel for treatment and follow-up visits. [6]

Pro tip: Use the "Advanced Search" on ClinicalTrials.gov to filter by condition, location, and phase simultaneously. This narrows hundreds of results to the handful of trials that genuinely match your situation.

Eligibility: Who Can and Cannot Join

Every trial has inclusion and exclusion criteria — the medical rules that determine who qualifies. Inclusion criteria describe the characteristics a participant must have: a confirmed diagnosis, a specific disease stage, age range, and sometimes prior treatment history. Exclusion criteria describe what disqualifies someone: co-existing conditions, certain medications, abnormal lab values, or recent participation in another trial. [7]

These criteria exist for two reasons: scientific validity and participant safety. A trial needs a homogeneous population to detect a treatment effect — if everyone is too different, the signal gets lost in the noise. Safety exclusions prevent exposing people to unnecessary risk. A patient with severe kidney disease, for example, may not clear the investigational product properly; excluding them protects them from harm the trial is not designed to manage.

Patients often ask whether exceptions are possible. The short answer is almost always no. Criteria are set in the protocol approved by ethics committees and regulators; the investigator cannot waive them at the bedside. If you do not meet the criteria as written, you are not eligible — and a trial that offers to "work with you" on criteria is almost certainly not following its own approved protocol.

Red flag: A trial that downplays or bends eligibility criteria to enroll you is violating the protocol that protects you. Legitimate trials enforce criteria strictly.

The Informed Consent Process

Informed consent is not a signature on a form — it is a conversation, and it must happen before any screening procedure. The consent document describes the purpose of the study, the procedures you will undergo, the known risks, potential benefits, alternatives to participation, and your rights as a research subject. You should receive a copy to take home, and the research team must answer every question before you sign. [8]

Key elements every consent form must include: a clear statement that this is research, not standard treatment; the experimental nature of the intervention; explanations of randomization and placebo if applicable; the expected duration of participation; the approximate number of participants; any costs you may bear; compensation for injury if applicable; and a contact for questions about your rights. If any of these are missing, the consent is incomplete.

Never sign a consent form under time pressure. A legitimate trial gives you days or weeks to decide. If someone pressures you to sign immediately — "the last spot is filling up" or "we need your answer today" — that is a serious red flag. Informed consent means consent without coercion, and coercion includes manufactured urgency.

Costs: Who Pays for What?

In a legitimate clinical trial, the investigational treatment itself is almost always provided at no cost to the participant. The sponsor — whether a pharmaceutical company, biotech firm, or academic institution — covers the cost of the investigational product. Many trials also cover study-related procedures: laboratory tests, imaging, and physician assessments that are required by the protocol. [9]

What the participant may pay: travel, accommodation, and routine care. Trials rarely cover transportation to and from the study site, lodging during treatment visits, or meals. Some offer stipends to offset these costs, but this varies widely. Routine medical care that you would need regardless of the trial — managing your underlying condition — remains your responsibility or your insurer's. These distinctions should be spelled out clearly in the consent form.

A trial that charges for the investigational product is not necessarily illegitimate, but it demands scrutiny. Some early-phase studies in countries without public research funding operate on a cost-recovery model. The key question is transparency: is the cost disclosed before you commit, and is it reasonable relative to the direct expenses of producing the cells? A trial that charges thousands of dollars without a clear accounting is operating more like a commercial clinic than a research study.

Critical question to ask: "What costs will I bear, exactly — and what does the sponsor cover? Can I see this in writing before I consent?"

Patient Rights and Protections

Research participants have rights that are protected by international standards — the Declaration of Helsinki and national regulations. You have the right to withdraw from a trial at any time, for any reason, without penalty and without losing access to your常规 medical care. You have the right to be informed of new findings that may affect your willingness to continue. You have the right to privacy — your data must be handled according to data protection laws. [10]

In the United States, trials operate under an Investigational New Drug application with the FDA. In Europe, under the European Medicines Agency's Clinical Trials Regulation. In Thailand, under the Thai FDA. Each framework requires ethics committee approval, ongoing safety reporting, and the right of regulators to inspect the trial site. A trial that cannot name the regulatory body overseeing it is not operating within a recognized framework.

Adverse event reporting is a critical protection. Every unexpected or serious medical event during the trial must be documented and reported to the ethics committee and regulators. If the safety profile shifts unfavorably, the trial can be paused or terminated. This is not a flaw — it is the system working as designed to protect you. A trial that downplays or dismisses side effects is subverting the safety infrastructure.

Red Flags in Trial Recruitment

Recognizing illegitimate trial recruitment is a skill — and the patterns are consistent. The most common red flag is the absence of a public registry listing. A close second is the use of patient testimonials as evidence of efficacy in the recruitment pitch — if the trial is still enrolling, no one knows whether it works yet, so testimonials are misleading at best. [11]

Other warning signs: a trial that requires payment for the investigational product without clear justification; a recruitment process that skips or rushes informed consent; a trial that cannot name its ethics committee or provide committee contact information; a sponsor that is also the treating physician with no independent oversight; and a trial that claims to treat many unrelated conditions under a single protocol — legitimate research studies one or two closely related indications, not a broad menu of diseases. [12]

Patient communities and advocacy groups can help. Organizations like the ALS Association, the Michael J. Fox Foundation, and disease-specific patient registries often maintain lists of actively recruiting trials vetted by their scientific advisory boards. Cross-referencing a trial against these lists adds an independent layer of verification.

Remember: A legitimate clinical trial wants you to understand the risks fully before you enroll. A questionable recruitment campaign wants you to focus on the promise and ignore the uncertainty.

What to Expect During Participation

Clinical trial participation follows a structured path: screening, enrollment, treatment, and follow-up. Screening may involve blood tests, imaging, and a detailed medical history review to confirm eligibility. Enrollment is the formal entry point — you sign the consent form and receive a unique participant identifier. Treatment follows the protocol exactly: specific doses at specific intervals. Follow-up visits are scheduled at pre-specified time points, often over months or years. [13]

Randomization and blinding are common in later-phase trials. You may be randomly assigned to receive the investigational treatment or a comparator — which could be a placebo or standard of care. In a double-blind trial, neither you nor the treating team knows which you are receiving. This is the gold standard for generating unbiased evidence, but it means you might not receive the active treatment. The consent form must disclose the probability — typically a 50% or 67% chance of receiving the experimental therapy.

The follow-up period is where the science happens. Every assessment, every blood draw, every questionnaire contributes to the dataset that will answer the study question. Skipping follow-up visits weakens the trial for everyone. Before enrolling, consider whether you can commit to the full follow-up schedule — including travel for in-person visits if the trial does not offer remote assessments.

Questions to Ask Before You Enroll

Clinical Trials vs. Commercial "Clinical Experience" Programs

The distinction between a registered clinical trial and a commercial "clinical experience" program is the most important concept in this guide. A trial is listed on a public registry, has ethics committee approval, follows a pre-specified protocol, and charges only for ancillary costs if anything. A clinical experience program is a commercial treatment using the language of research to market itself — it is not a trial, regardless of what the clinic calls it. [14]

Patients should understand that paying to participate in unregistered "research" offers none of the protections described above. There is no DSMB monitoring safety, no regulator inspecting the site, no requirement to publish results, and no assurance that the cells meet the quality standards expected of an investigational product. The term "clinical experience" is a marketing label, not a regulatory category.

Bottom line: If you are paying thousands of dollars for "stem cell research" that is not on a public registry, you are not in a clinical trial — you are a customer in a commercial treatment program. Knowing the difference protects you.

Limitations and Realistic Expectations

Clinical trial participation is not a guarantee of benefit. Most investigational treatments do not prove effective — that is the nature of research. Phase II trials have roughly a 30% success rate in advancing to Phase III. For every trial that produces a breakthrough, multiple trials produce negative or inconclusive results. Enter with hope, but ground that hope in the reality that you are contributing to knowledge, not purchasing a cure. [15]

The time commitment is real and often underestimated. Trials can span months or years of follow-up visits. Travel to a distant site may be required multiple times. The screening process alone can take weeks before you know whether you are eligible. Patients considering trial participation should plan for the logistics as carefully as they plan for the treatment itself.

MSC therapy, even in a trial setting, is still an investigational intervention. While the safety record of properly manufactured MSCs is strong in published trials, risks exist — infusion reactions, immune sensitization, and in rare cases, ectopic tissue formation. The informed consent document is your best source of trial-specific risk information. Read it carefully, and ask about anything you do not understand.

Frequently Asked Questions

How do I find MSC clinical trials near me?

Search ClinicalTrials.gov with the keywords "mesenchymal stem cells" and your condition. Filter by country and "Recruiting" status. The WHO ICTRP and EU Clinical Trials Register are complementary search tools for non-U.S. trials. Your treating physician may also be aware of actively enrolling studies in your region.

Do I have to pay to participate in a clinical trial?

In most cases, the investigational product and study-related procedures are provided at no cost. Travel, lodging, and routine care are typically the participant's responsibility. Some trials offer stipends. A trial that charges thousands for the treatment itself should be scrutinized carefully — it may be a commercial program, not registered research.

What if I change my mind after enrolling?

You have the right to withdraw at any time, for any reason, without penalty and without losing access to your常规 medical care. Your decision to withdraw must be respected immediately. You cannot be pressured to stay, and your relationship with your usual physicians should not be affected.

How do I know if a trial is legitimate?

Check that it is listed on a public registry like ClinicalTrials.gov. Confirm the sponsor is a recognized research institution or company with a verifiable track record. Verify that an ethics committee has approved the study and can be contacted. If all three conditions are met, the trial meets basic legitimacy standards.

Can I participate in a trial in another country?

Yes — many trials accept international participants, but logistics become more complex. You may need to arrange travel and accommodation for multiple visits. Regulatory protections vary by country; a trial in Country A is regulated by Country A's authorities, regardless of where you live. Confirm the regulatory framework before committing to international participation.

What is the difference between Phase I, II, and III?

Phase I studies safety and dosing in a small group, often 20-80 people. Phase II studies efficacy signals in a larger group, typically 100-300. Phase III compares the treatment against placebo or standard care in hundreds or thousands, generating the evidence needed for regulatory approval. Each phase answers a different question.

References
  1. Friedman LM, Furberg CD, DeMets DL, Reboussin DM, Granger CB. Fundamentals of Clinical Trials. 5th ed. Springer. 2015. doi:10.1007/978-3-319-18539-2 ↩
  2. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov Results Database — Update and Key Issues. New England Journal of Medicine. 2011;364(9):852-860. doi:10.1056/NEJMsa1012065 ↩
  3. Emanuel EJ, Wendler D, Grady C. What Makes Clinical Research Ethical? JAMA. 2000;283(20):2701-2711. doi:10.1001/jama.283.20.2701 ↩
  4. ClinicalTrials.gov. Trends, Charts, and Maps. U.S. National Library of Medicine. 2026. https://clinicaltrials.gov/ct2/resources/trends ↩
  5. World Health Organization. International Clinical Trials Registry Platform (ICTRP). 2026. https://www.who.int/clinical-trials-registry-platform ↩
  6. Tse T, Fain KM, Zarin DA. How to avoid common problems when using ClinicalTrials.gov in research. BMJ. 2018;361:k1452. doi:10.1136/bmj.k1452 ↩
  7. Kim ES, Bruinooge SS, Robarts S, et al. Broadening eligibility criteria to make clinical trials more representative. New England Journal of Medicine. 2017;377(8):793-795. doi:10.1056/NEJMsb1706045 ↩
  8. United States Department of Health and Human Services. Federal Policy for the Protection of Human Subjects ('Common Rule'). 45 CFR 46. 2018. https://www.hhs.gov/ohrp/regulations-and-policy/regulations/45-cfr-46/ ↩
  9. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273-286. doi:10.1093/biostatistics/kxx069 ↩
  10. World Medical Association. Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053 ↩
  11. Turner L. ClinicalTrials.gov, stem cells and 'pay-to-participate' clinical studies. Regenerative Medicine. 2017;12(6):705-719. doi:10.2217/rme-2017-0015 ↩
  12. Sipp D, Caulfield T, Kaye J, et al. Marketing of unproven stem cell-based interventions: a call to action. Science Translational Medicine. 2017;9(397):eaag0426. doi:10.1126/scitranslmed.aag0426 ↩
  13. Getz KA, Campo RA, Kaitin KI. Variability in protocols and patient populations across clinical trials submitted to the FDA. Clinical Trials. 2018;15(3):271-277. doi:10.1177/1740774518763667 ↩
  14. Connolly R, O'Brian T, Flaherty G. Stem cell tourism — a web-based analysis of clinical services available to international travellers. Travel Medicine and Infectious Disease. 2014;12(6):695-701. doi:10.1016/j.tmaid.2014.09.008 ↩
  15. Hay M, Thomas DW, Craighead JL, Ecnomides C, Rosenthal J. Clinical development success rates for investigational drugs. Nature Biotechnology. 2014;32(1):40-51. doi:10.1038/nbt.2786 ↩